Biotech is back, with Craig Ackerman

Launching new therapies has been a core competency of pharma marketers as long as the profession has existed. But the rules of the game are always changing, and the combination of new therapies and new technologies makes it a perennial topic at meetings like Reuters Pharma USA.

In Philadelphia this month, Editor in Chief Jonah Comstock spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, the GLP-1 market, and how biotech markets are finally coming back after the pandemic.

Check out the wide-ranging conversation from the show below.